drugset / Trial / NCT06800157
Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase IIa study is designed to evaluate the dose-response relationship, efficacy, safety, and tolerability of LW402 tablets administered for 12 weeks in adult patients with active rheumatoid arthritis receiving background methotrexate (MTX) therapy.
Timeline
- Start
- 2023-02-27
- Primary completion
- 2024-05-26
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LW402 | Unknown | 50 mg | Oral |
| Subject | LW402 | Unknown | 125 mg | Oral |
| Background | Methotrexate | Small molecule | — | — |